Benetello P, Furlanut M, Zara G, Baraldo M, Hassan E
Institute of Neurology, University of Padua, Italy.
Eur Neurol. 1993;33(1):69-73. doi: 10.1159/000116905.
The paper reports plasma levels of levodopa (LD), its main metabolites [dopamine, dihydroxyphenylacetic acid, homovanillic acid, 3-O-methyldopa (3-O-MD)] and carbidopa in 14 parkinsonian patients first treated with Sinemet and thereafter with Sinemet-CR4. A good relationship was observed between LD plasma levels and pharmacological effects. While the LD area under the curve increased after Sinemet-CR4, the same was not observed with metabolites, except with 3-O-MD. The experiments in volunteer subjects confirmed the increase in 3-O-MD in plasma after Sinemet-CR4. Higher levels were observed also in the CSF with a reduction of LD concentrations. This seems to corroborate the hypothesis of an interference with LD passage through the blood-brain barrier in humans.
该论文报告了14名帕金森病患者血浆中左旋多巴(LD)、其主要代谢产物[多巴胺、二羟基苯乙酸、高香草酸、3 - O - 甲基多巴(3 - O - MD)]以及卡比多巴的水平。这些患者最初接受息宁治疗,之后接受息宁控释片治疗。观察到血浆中左旋多巴水平与药理作用之间存在良好的相关性。虽然息宁控释片治疗后左旋多巴的曲线下面积增加,但除3 - O - MD外,代谢产物的情况并非如此。在志愿者受试者中进行的实验证实了息宁控释片治疗后血浆中3 - O - MD增加。脑脊液中也观察到较高水平的3 - O - MD,同时左旋多巴浓度降低。这似乎证实了在人体中左旋多巴通过血脑屏障受到干扰的假说。